Zealand's Dutch leading investor looks forward to two hectic years: "There are multiple triggers"
Head of Investments for the Dutch family foundation Van Herk, Dharminder Chahal, is looking forward to getting certainty over a number of central points in Zealand Pharma's business plan over the next two years, where the company reaches several milestones.
It will be an eventful year for Zealand Pharma, including both phase III results and approval applications, which can significantly change the company's market value.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
